3
Orphan Designations
0 approved, 3 designated
0
FDA Approvals
1
Active Trials
200 recruiting
4
Rare Diseases
across 6 areas
0
News (30d)
Quiet
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd is a company with 3 orphan drug designations across 4 rare diseases. Active clinical trials in 1 indication. 5 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| diabetes mellitus | - | Des.TrialAppr. |
| gastric cancer | antibody drug conjugate consisting of PM-012D antibody and linker-payload Pym-PEG8-Val-Ala-PAB-Exd | Des.TrialAppr. |
| malignant pancreatic neoplasm | antibody drug conjugate consisting of PM-012D antibody and linker-payload Pym-PEG8-Val-Ala-PAB-Exd | Des.TrialAppr. |
| mantle cell lymphoma | an antibody-drug conjugate composed of the humanized monoclonal antibody against ROR1, conjugated to MMAE through a mc-vc-PAB cleavable linker | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
33
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
5
affecting portfolio
0% of portfolio targets high unmet need diseases
33
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
5
affecting portfolio